Worm-Fighting combo pill tested in kids, but trial stopped early

NCT ID NCT05124691

Terminated Disease control Sponsor: Barcelona Institute for Global Health Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a new pill combining two drugs (albendazole and ivermectin) to treat several types of intestinal worms in children and young adults aged 5 to 18. The goal was to see if the combination worked better than the standard single drug. However, the trial was terminated early, so the planned results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: albendazole and ivermectin combination pill
What this could lead to: If it had succeeded, this combination could have offered a more effective single treatment for several types of intestinal worms, especially those resistant to current drugs.
What could go wrong: The trial was terminated, so we don't have full results. Early-stage research often fails to show benefit or may reveal safety issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELMINTHES; INFESTATION, INTESTINAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

helminthiasis hookworm infectious disease intestinal helminthiasis strongyloidiasis trichuriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HELMINTHES; INFESTATION, INTESTINAL

Contacts and locations

Locations

Bahir Dar University, Colleges of Medicine and Health Sciences (BDU-CMHS)

Bahir Dar, P.O. Box 79, Ethiopia
Centro de Investigação em Saúde da Manhiça (CISM)

Manhiça, Maputo Province, 1929, Mozambique
Kenya Medical Research Institute (KEMRI)

Nairobi, 54840-00200, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.